Ambrisentan is a selective endothelin type-A (ETA) receptor antagonist that reduces pulmonary vascular resistance, used in the management of pulmonary arterial hypertension. Simson Pharma's Ambrisentan reference standard and impurities support stability-indicating assay development for this specialised cardiopulmonary therapy.
Simson Pharma Global Ltd. (UK) and Simson Pharma Global LLC (USA) supply high-quality Ambrisentan Reference Standards, pharmacopoeial reference materials, and its related impurities to pharmaceutical manufacturers, CROs, analytical laboratories, universities, and regulatory organizations worldwide. To service the Europe and America market efficiently, Simson Pharma Limited has set up Simson Pharma Global Ltd. in United Kingdom and Simson Pharma Global LLC in USA respectively.